IL-18 single nucleotide polymorphisms in hematologic malignancies with HLA matched sibling donor allogeneic hematopoietic stem cell transplantation.

Xiaojin Cai; Axia Song; Hua Wang; Ping Zhang; Guixin Zhang; Fan Yang; Jialin Wei; Qiaoling MA; Zhangsong Yan; Erlie Jiang; Yong Huang; Donglin Yang; Mei Wang; Yi HE; Mingzhe Han; Sizhou Feng

Return

IL-18 single nucleotide polymorphisms in hematologic malignancies with HLA matched sibling donor allogeneic hematopoietic stem cell transplantation.

Author: Xiaojin CAI ¹ ; Axia SONG ¹ ; Hua WANG ¹ ; Ping ZHANG ¹ ; Guixin ZHANG ¹ ; Fan YANG ¹ ; Jialin WEI ¹ ; Qiaoling MA ¹ ; Zhangsong YAN ¹ ; Erlie JIANG ¹ ; Yong HUANG ¹ ; Donglin YANG ¹ ; Mei WANG ¹ ; Yi HE ¹ ; Mingzhe HAN ¹ ; Sizhou FENG ¹
Author Information

1. State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China.
Publication Type:Journal Article
MeSH: Adolescent; Adult; Child; Child, Preschool; Disease-Free Survival; Female; Genotype; Graft vs Host Disease; epidemiology; Hematologic Neoplasms; genetics; therapy; Hematopoietic Stem Cell Transplantation; adverse effects; methods; Humans; Incidence; Interleukin-18; genetics; Male; Middle Aged; Polymorphism, Single Nucleotide; Siblings; Tissue Donors; Transplantation, Homologous; Young Adult
From: Chinese Journal of Hematology 2014;35(3):215-220
CountryChina
Language:Chinese
Abstract:
OBJECTIVETo explore the impact of interleukin-18 (IL-18) single nucleotide polymorphisms on outcomes of hematologic malignancies with HLA-matched sibling donor hematopoietic stem cell transplantation (allo-HSCT).
METHODSSingle- nucleotide polymorphisms in IL-18 promoter was detected by PCR-sequence-specific primer analysis (PCR-SSP) in 93 recipients and their HLA matched sibling donors. Hematopoietic reconstitution, incidences of graft versus host disease (GVHD) and infections, transplant related mortality (TRM), and disease free survival (DFS) were analyzed.
RESULTSIn comparison with -137 G/C+C/C donor genotype, patients with -137 G/G donor genotype had shorter duration of neutrophil recovery [15(11-23) days vs 17(11-24) days, P=0.01], higher incidence of extensive chronic GVHD (20.6% vs 3.3%, P=0.029), but no difference in the interval of platelet recovery [20(11-46) days vs 20(7-38) days, P=0.844]. The incidence of extensive chronic GVHD in -607 C/C donor genotype (31.6%) was significantly higher than that (10.8%) in C/A + A/A donor genotype (P=0.024). Recipients with -607 C/C genotype also had higher incidence (33.3%) of extensive chronic GVHD than those with C/A+A/A genotype (10.7%, P=0.016). There were no differences in acute GVHD, TRM, and DFS between different genotypes.
CONCLUSIONIL-18 -137 G homozygous genotype in donor facilitated neutrophil reconstitution, but increased the risk of extensive chronic GVHD in patients with allo-HSCT.